COFCO Biotechnology Co., Ltd.

SZSE:000930 Stock Report

Market Cap: CN¥10.7b

COFCO Biotechnology Past Earnings Performance

Past criteria checks 0/6

COFCO Biotechnology's earnings have been declining at an average annual rate of -30.5%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 0.6% per year.

Key information

-30.5%

Earnings growth rate

-30.5%

EPS growth rate

Chemicals Industry Growth12.1%
Revenue growth rate0.6%
Return on equity-2.3%
Net Margin-1.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

Oct 14
COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

Sep 30
We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

Jul 17
COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Jun 03
COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

Apr 17
Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

Mar 07
COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

Revenue & Expenses Breakdown

How COFCO Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:000930 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420,782-259830159
30 Jun 2420,980-205811175
31 Mar 2420,588-578777170
31 Dec 2320,379-602789165
30 Sep 2319,743-240797149
30 Jun 2318,619-63798118
31 Mar 2319,060711794119
01 Jan 2319,9181,059807133
30 Sep 2220,3701,16077785
30 Jun 2222,1421,215780114
31 Mar 2223,3201,123827132
01 Jan 2223,5601,130815119
30 Sep 2124,011994837135
30 Jun 2122,630928840144
31 Mar 2121,460848795105
31 Dec 2019,909593799114
30 Sep 2019,5697371,028131
30 Jun 2019,8837721,263101
31 Mar 2018,9356361,56591
31 Dec 1919,4725931,81087
30 Sep 1918,4243321,79965
30 Jun 1917,7203041,92180
31 Mar 1917,8504301,84682
31 Dec 1817,7044831,85196
30 Sep 1824,4801,2542,789176
30 Jun 1821,8481,0702,336168
31 Mar 1818,8219672,058146
31 Dec 1715,8929291,768101
30 Sep 176,16423746022
30 Jun 175,8983394970
31 Mar 175,8542325550
31 Dec 165,6031275580
30 Sep 165,446-8016080
30 Jun 165,593-1,0836120
31 Mar 166,186-1,2655530
31 Dec 156,457-1,4185350
30 Sep 156,704-5094560
30 Jun 157,155-3124750
31 Mar 156,930-1664540
31 Dec 147,153354630
30 Sep 147,102244900
30 Jun 147,074324780
31 Mar 147,186394560
31 Dec 137,340514590

Quality Earnings: 000930 is currently unprofitable.

Growing Profit Margin: 000930 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000930 is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.

Accelerating Growth: Unable to compare 000930's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 000930 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-4.7%).

Return on Equity

High ROE: 000930 has a negative Return on Equity (-2.29%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 18:01
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

COFCO Biotechnology Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun HuangChina Merchants Securities Co. Ltd.
Xia ShengCitic Securities Co., Ltd.
Jian ZhouGuoyuan Securities Co., Ltd.